Related Experiment Video
Updated: May 9, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Human T-Cell Lymphotropic Virus (HTLV 1/2) in Ecuador: Time for Action
Miguel Angel Garcia-Bereguiain1, Solon Alberto Orlando2,3, Melissa Joseth Carvajal Capa4
1One Health Research Group, Universidad de Las Américas, Quito, Ecuador.
Abstract:
The human T-cell lymphotropic viruses of type 1 and 2 (HTLV 1/2) are retroviruses with estimations of 10 million people infected worldwide. HTLV 1/2 viruses are endemic in South America where Indigenous and Afro American populations are considered of high risk. Although several case reports of HTLV 1/2 associated pathologies and some prevalence studies have been reported in Ecuador, the country lacks a national surveillance and control program, and no screening of blood or organ donors is currently done. We discuss the problems associated to HTLV 1/2 in Ecuador and propose a strategy to improve a surveillance and control program.

